# A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients

> **NCT02599779** · PHASE2 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 4 (actual)

## Conditions studied

- Stage IV Renal Cell Cancer AJCC V7

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT02599779
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2021-08
- **Final completion:** 2021-08-05
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2021-09-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02599779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02599779, "A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02599779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*